Study on TIL for the Treatment of Advanced Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
20-60 participants are expected to be enrolled for the Phase I clinical trial which is
further divided into two parts: a "3+3" dose escalation study and an expanded enrollment
study.
The Phase I clinical trial is expected to be finished in 36 months. To be specific, the dose
escalation study plans to include patients with advanced malignant solid tumors with clear
pathological diagnosis, including melanoma, cervical cancer, head and neck squamous cell
tumors, non-small cell lung cancer and breast cancer, etc.; while the expanded enrollment
study plans to include those with melanoma, cervical cancer, and head and neck squamous cell
tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Gencells Therapeutics Co., Ltd.
Collaborator:
Kun Tuo Medical Research & Development (Beijing) Co.,Ltd.